Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKinsey
Chinese Patent Office
Healthtrust
Teva
Dow
US Army
Mallinckrodt
Fuji

Generated: September 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,818,226

« Back to Dashboard

Summary for Patent: 6,818,226
Title: Dermal penetration enhancers and drug delivery systems involving same
Abstract:A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
Inventor(s): Reed; Barry Leonard (Strathmore, AU), Morgan; Timothy Matthias (Parkville, AU), Finnin; Barrie Charles (Glen Iris, AU)
Assignee: ACRUX DDS Pty. Ltd. (Victoria, AU)
Application Number:09/910,780
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,818,226
Patent Claim Types:
see list of patent claims
Delivery; Compound; Use; Device;

Drugs Protected by US Patent 6,818,226

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,818,226

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPN8144/96Feb 19, 1996

International Family Members for US Patent 6,818,226

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 324865 ➤ Try a Free Trial
Austria 410136 ➤ Try a Free Trial
Austria 472997 ➤ Try a Free Trial
Australia 1713497 ➤ Try a Free Trial
Australia 5258999 ➤ Try a Free Trial
Australia 706967 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Healthtrust
Farmers Insurance
QuintilesIMS
Medtronic
US Department of Justice
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.